H.C. Wainwright lowered the firm’s price target on Opthea to $12 from $14 and keeps a Buy rating on the shares. The firm updated its sozinibercept launch revenue estimates from mid/late 2025 to 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPT:
- Opthea Reports Full-Year Financial Results and Business Updates
- Opthea reports FY24 adjusted EPS ($27.27) vs. ($30.61) last year
- Opthea Limited: Revenues Up, Losses Widen
- Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024
- Opthea Limited Showcases at Ophthalmology Event